Abstract:Background Cancer-related pain often requires opioid treatment with opioid-induced constipation (OIC) as its most frequent gastrointestinal side-effect. Both for prevention and treatment of OIC osmotic (e.g. polyethylene glycol) and stimulant (e.g. bisacodyl) laxatives are widely used. Newer drugs such as the peripherally acting μ-opioid receptor antagonists (PAMORAs) and naloxone in a fixed combination with oxycodone have become available for the management of OIC. This systematic review and meta -analysis aims to give an overview of the scientific evidence on pharmacological strategies for the prevention and treatment of OIC in cancer patients. Methods A systematic search in PubMed, Embase, Web of Science and the Cochrane Library was completed from inception up to 22 October 2022. Randomized and non-randomized studies were systematically selected. Bowel function and adverse drug events were assessed. Results Twenty trials (prevention: five RCTs and three cohort studies; treatment: ten RCTs and two comparative cohort studies) were included in the review. Regarding the prevention of OIC, three RCTs compared laxatives with other laxatives, finding no clear differences in effectivity of the laxatives used. One cohort study showed a significant benefit of magnesium oxide compared with no laxative. One RCT found a significant benefit for the PAMORA naldemedine compared with magnesium oxide. Preventive use of oxycodone/naloxone did not show a significant difference in two out of three other studies compared to oxycodone or fentanyl. A meta -analysis was not possible. Regarding the treatment of OIC, two RCTs compared laxatives, of which one RCT found that polyethylene glycol was significantly more effective than sennosides. Seven studies compared an opioid antagonist (naloxone, methylnaltrexone or naldemedine) with placebo and three studies compared different dosages of opioid antagonists. These studies with opioid antagonists were used for the meta -analysis. Oxycodone/naloxone showed a significant improvement in Bowel Function Index compared to oxycodone with laxatives (MD −13.68; 95 % CI −18.38 to −8.98; I 2 = 58 %). Adverse drug event rates were similar amongst both groups, except for nausea in favour of oxycodone/naloxone (RR 0.51; 95 % CI 0.31–0.83; I 2 = 0 %). Naldemedine (NAL) and methylnaltrexone (MNTX) demonstrated significantly higher responder rates compared to placebo (NAL: RR 2.07, 95 % CI 1.64–2.61, I 2 = 0 %; MNTX: RR 3.83, 95 % CI 2.81–5.22, I 2 = 0 %). With regard to adverse events, abdominal pain was more present in treatment with methylnaltrexone and diarrhea was significantly more present in treatment with naldemedine. Different dosages of methylnaltrexone were not significantly different with regard to both efficacy and adverse drug event rates. Conclusions Magnesium oxide and naldemedine are most likely effective for prevention of OIC in cancer patients Naloxone in a fixed combination with oxycodone, naldemedine and methylnaltrexone effectively treat OIC in cancer patients with acceptable adverse events. However, their effect has not been compared to standard (osmotic and stimulant) laxatives. More studies comparing standard laxatives with each other and with opioid antagonists are necessary before recommendations for clinical practice can be made.

The role of loperamide in gastrointestinal disorders

Loperamide in chronic diarrhea and after ileostomy: a placebo-controlled double-blind cross-over study

Pharmacologic Agents for Chronic Diarrhea

Loperamide, an Antidiarrheal Agent, Induces Apoptosis and DNA Damage in Leukemia Cells.

Adverse Effects of Drugs Used in the Management of Constipation and Diarrhoea

Effect Of Lactobacillus On Toll-Like Receptors Expression And Bacterial Translocation In Antibiotic Diarrhea Rats

Combination of Galacto-Oligosaccharides and Wheat Peptides Synergistically Relieved Constipation Via Regulating Water Transport, Gut Barrier, Inflammation and Gut Microbiota

Novel Oral Therapies for Opioid-induced Bowel Dysfunction in Patients with Chronic Noncancer Pain

Loperamide, an antidiarrhea drug, has antitumor activity by inducing cell apoptosis

Novel insights into mechanisms of inhibition of colonic motility by loperamide

Bifidobacterium longum S3 alleviates loperamide-induced constipation by modulating intestinal acetic acid and stearic acid levels in mice

Opioids and the Gastrointestinal Tract: The Role of Peripherally Active μ-Opioid Receptor Antagonists in Modulating Intestinal Permeability

Pharmacologic management of diarrhea in patients with short bowel syndrome

Control of irinotecan-induced diarrhea by octreotide after loperamide failure

Diarrhoea of unknown cause: medical treatment in a stepwise manner

Ciprofloxacin and Loperamide in the Treatment of Bacillary Dysentery

Impact of the probiotic Bacillus coagulans on loperamide-induced delayed bowel movement in Sprague–Dawley rats

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis

Lubiprostone in constipation: clinical evidence and place in therapy

Lactobacillus paracasei subsp. paracasei NTU 101 lyophilized powder improves loperamide-induced constipation in rats